Subvisible Particles in IVIg Formulations Activate Complement in Human Serum-Reference-Cited by-同舟云学术

Subvisible Particles in IVIg Formulations Activate Complement in Human Serum

Published:2020-01 Issue:1 Volume:109 Page:558-565
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Chisholm Carly F.,Behnke William,Pokhilchuk Yekaterina,Frazer-Abel Ashley A.,Randolph Theodore W.

Funder

NIH

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference61 articles.

1. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory;Bertolotto;J Neurol Neurosurg Psychiatry,2002

2. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis;Deisenhammer;J Neurol,2004

3. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology;Goodin;Neurology,2007

4. Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications–introduction;Hartung;J Neurol,2004

5. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference;Hartung;Eur J Neurol,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticulate impurities in the pharmaceutical excipient trehalose induce an early immune response;European Journal of Pharmaceutics and Biopharmaceutics;2023-08

2. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo®] Obtained from a Manufacturing Process Preserving IgA/IgM Potential of Human Plasma;Drugs in R&D;2023-07-19

3. Machine learning approaches to root cause analysis, characterization, and monitoring of subvisible particles in monoclonal antibody formulations;Biotechnology and Bioengineering;2022-10-03

4. Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates;Frontiers in Immunology;2022-07-27

5. Effects of Transportation of IV Bags Containing Protein Formulations Via Hospital Pneumatic Tube System: Particle Characterization by Multiple Methods;Journal of Pharmaceutical Sciences;2022-04